Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.64 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.64 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.64 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.57 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.57 |
| ▸ | AMD1 | P17707 | 2/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 2/20 | 0.51 |
| ▸ | AHCY | P23526 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.45 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.45 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18127419 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9109513 | 1.00 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL16976155 | 0.86 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9104850 | 0.86 | PI4KA (0.61) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL10284449 | 0.85 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9104284 | 0.84 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL15509286 | 0.84 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9108235 | 0.84 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9913533 | 0.84 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL9108231 | 0.84 | PI4KA (0.59) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11633420-B2 | Method of treating leukemia | Epizyme, Inc. (US) | 2023-04-25 | — | — | US | disclosed |
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-03-14 | — | — | US | disclosed |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2021-08-19 | — | — | US | disclosed |
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. | 2018-10-04 | — | — | US | disclosed |
| EP-2646444-B1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS AS MODULATORS OF EPIGENETIC ENZYMES | EPIZYME INC (US) | 2016-03-16 | — | — | EP | disclosed |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | Epizyme, Inc. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8580762-B2 | Substituted purine and 7-deazapurine compounds | Epizyme, Inc. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180280422-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-11603570-B2 | Methods for the detection and treatment of leukemias that are responsive to DOT1L inhibition | MLLT1, MCL1, BCR | PI4KA 3164/4885PI4K2B 2613/4885PI4K2A 2893/4885 |
| US-11633420-B2 | Method of treating leukemia | DOT1L, MCL1, CARM1 | PI4KA 2351/4885PI4K2B 2334/4885PI4K2A 2248/4885 |
| US-20210252035-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-20150366893-A1 | SUBSTITUTED PURINE AND 7-DEAZAPURINE COMPOUNDS | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | PI4KA 3070/4885PI4K2B 3345/4885PI4K2A 3188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.